The present invention relates to a vaccine comprising at least one peptide consisting of 7 to 19 amino acid residues consisting of the amino acid sequence (X 3 ) m KDX 2 QLGX 1 (SEQ ID No. 99), wherein X 1 is an amino acid residue selected from the group consisting of alanine, asparagine, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, serine, threonine, tyrosine and valine, X 2 is an amino acid residue selected from the group consisting of alanine, arginine, histidine, isoleucine, leucine, lysine, methionine, threonine, tyrosine and valine. X 3 is (X 4 ) n ANISX 5 (SEQ ID No. 100) or an N-terminal truncated fragment thereof consisting of 1 to 4 amino acid residues, X 4 is VVASQLR (SEQ ID No. 101) or an N-terminal truncated fragment thereof consisting of 1 to 6 amino acid residues, X 5 is an amino acid residue selected from the group consisting of alanine, asparagine, glutamine, glutamic acid, histidine, arginine, isoleucine, lysine, methionine, serine and threonine, m is 0 or 1, and n is 0 or 1, wherein said at least one peptide is coupled or fused to a carrier comprising at least one T-cell epitope.
